Speakers | Kisaco Research

Speakers

Reproductive Health Innovation Summit
13-14 February, 2024
Boston, USA
  • Author:

    Margaret Malone

    Healthtech Investor
    Flare Capital

    Margaret Malone

    Healthtech Investor
    Flare Capital
  • Author:

    Vrunda Desai

    MD, FACOG, Vice President of Medical Affairs,
    CooperSurgical

    Vrunda Desai

    MD, FACOG, Vice President of Medical Affairs,
    CooperSurgical
  • Author:

    Bethany Corbin

    Founder & CEO
    FemInnovation

    Bethany Corbin

    Founder & CEO
    FemInnovation
  • Author:

    Fahimeh Sasan

    Chief Innovation Officer
    Kindbody

    Fahimeh Sasan

    Chief Innovation Officer
    Kindbody
  • Author:

    Liza Kunz

    Systems Director, Endocrinology & Reproductive Health
    Abbott

    Liza Kunz

    Systems Director, Endocrinology & Reproductive Health
    Abbott
  • Author:

    Ru-fong Joanne Cheng

    Director, Women’s Health Innovations
    Bill & Melinda Gates Foundation

    Ru-fong Joanne Cheng

    Director, Women’s Health Innovations
    Bill & Melinda Gates Foundation
  • Author:

    Sasha Ottey, MHA, MT, (ASCP)

    Executive Director
    PCOS Challenge: The National Polycystic Ovary Syndrome Association

    Sasha Ottey, MHA, MT, (ASCP)

    Executive Director
    PCOS Challenge: The National Polycystic Ovary Syndrome Association
  • Author:

    Leigh Allen

    Program Officer
    Eunice Kennedy Shriver National Institute of Child Health and Human Development

    Leigh Allen

    Program Officer
    Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • Author:

    Everett Hanford

    Region 1 Director of New England
    U.S. Department of Health and Human Services

    Everett Hanford

    Region 1 Director of New England
    U.S. Department of Health and Human Services
  • Author:

    Daniel Johnston

    Chief, Contraception Research Branch
    Eunice Kennedy Shriver National Institute of Child Health and Human Development

    Daniel Johnston

    Chief, Contraception Research Branch
    Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • Author:

    David Sable

    Life Sciences Portfolio Manager
    Special Situations Funds

    David Sable

    Life Sciences Portfolio Manager
    Special Situations Funds
  • Author:

    Carmen Messerlian

    Founder & President
    Vie Science, Inc.

    Carmen Messerlian

    Founder & President
    Vie Science, Inc.
  • Author:

    Diana Contreras

    Chief Health Strategy Officer
    Planned Parenthood Federation of America

    Diana Contreras

    Chief Health Strategy Officer
    Planned Parenthood Federation of America
  • Author:

    Jessica Bell van der Wal

    Co-Founder and CEO
    Frame Fertility

    Jessica Bell van der Wal

    Co-Founder and CEO
    Frame Fertility
  • Author:

    Nada Hanafi

    SVP - Regulatory Strategy
    Veranex

    Nada Hanafi

    SVP - Regulatory Strategy
    Veranex
  • Author:

    Kevin Eisenfrats

    Co-Founder & CEO
    Contraline

    Kevin Eisenfrats

    Co-Founder & CEO
    Contraline
  • Author:

    Anne Morrisey

    CEO and Founder
    May Health

    Anne Morrisey

    CEO and Founder
    May Health
  • Author:

    Yaron Silberman

    CEO
    BAIBYS™ Fertility

    Yaron Silberman

    CEO
    BAIBYS™ Fertility
  • Author:

    Mary Frank

    Director of Strategic Initiatives
    National Abortion Federation

    Mary Frank

    Director of Strategic Initiatives
    National Abortion Federation
  • Author:

    Michelle Perugini

    CEO & Co-Founder
    Presagen

    Michelle Perugini

    CEO & Co-Founder
    Presagen
  • Author:

    Anita Garg

    Senior Director Strategy
    Population Council

    Anita Garg

    Senior Director Strategy
    Population Council
  • Author:

    Christy Prada

    CEO
    Future Fertility

    Christy Prada

    CEO
    Future Fertility
  • Author:

    Heather Bowerman

    CEO and Founder
    DotLab

    Heather Bowerman

    CEO and Founder
    DotLab
  • Author:

    Naseem Sayani

    Co-Founder & Managing Director
    Emmeline Ventures

    Naseem Sayani

    Co-Founder & Managing Director
    Emmeline Ventures
  • Author:

    Donna Russell

    CEO
    Precia Group

    Donna Russell

    CEO
    Precia Group
  • Author:

    Stasia Obremskey

    Managing Director
    RH Capital

    Before joining, Stasia served in 2018 as the first Fellow of the Tara Health Foundation. She has more than twenty-five years of experience providing financial and strategic planning consulting to organizations in the U.S. and Asia. She has joined management teams as the interim Chief Financial Officer on a short term and extended term basis to provide finance, accounting and strategic planning expertise to startups, fast growing companies and non-profit organizations. Current and past clients include 18Birdies, Posit Science, Circlepoint, West Shore Technologies and We Care Solar. She has lived for over 8 years in Bangkok, Thailand and Hong Kong, China. She began her consulting career as a management consultant with Bain & Company. Previously, she worked in investment banking for Morgan Stanley & Co. She holds a bachelor’s degree in Business Administration with a concentration in finance from the University of Notre Dame and an MBA from the Harvard Graduate School of Business. In addition to her consulting work, she has extensive experience as a member of several nonprofit boards where she has held a number of leadership positions.

    Stasia Obremskey

    Managing Director
    RH Capital

    Before joining, Stasia served in 2018 as the first Fellow of the Tara Health Foundation. She has more than twenty-five years of experience providing financial and strategic planning consulting to organizations in the U.S. and Asia. She has joined management teams as the interim Chief Financial Officer on a short term and extended term basis to provide finance, accounting and strategic planning expertise to startups, fast growing companies and non-profit organizations. Current and past clients include 18Birdies, Posit Science, Circlepoint, West Shore Technologies and We Care Solar. She has lived for over 8 years in Bangkok, Thailand and Hong Kong, China. She began her consulting career as a management consultant with Bain & Company. Previously, she worked in investment banking for Morgan Stanley & Co. She holds a bachelor’s degree in Business Administration with a concentration in finance from the University of Notre Dame and an MBA from the Harvard Graduate School of Business. In addition to her consulting work, she has extensive experience as a member of several nonprofit boards where she has held a number of leadership positions.

  • Author:

    Natalie Birnbaum

    Principal Owner, Attorney
    Repro Solutions

    Natalie Birnbaum

    Principal Owner, Attorney
    Repro Solutions
  • Author:

    Kristin Brogaard

    CSO & Co-Founder
    Inherent Biosciences Inc.

    Kristin Brogaard

    CSO & Co-Founder
    Inherent Biosciences Inc.
  • Author:

    Ashley Crafton

    CEO
    Galena Innovations

    Ashley Crafton

    CEO
    Galena Innovations
  • Author:

    Valerie Palmieri

    CEO
    MOMENTUM Consulting

    Valerie Palmieri

    CEO
    MOMENTUM Consulting
  • Author:

    Nader AlSalim

    Founder & CEO
    Gaia

    Nader AlSalim

    Founder & CEO
    Gaia
  • Author:

    Samantha Miller

    Co-Founder & Co-CEO
    Cadence Health

    Samantha Miller

    Co-Founder & Co-CEO
    Cadence Health
  • Author:

    Nigina Nuntean

    Head of Innovation Unit
    United Nations Population Fund

    Nigina Nuntean

    Head of Innovation Unit
    United Nations Population Fund
  • Author:

    Monica Cepak

    CEO
    Wisp

    Monica Cepak

    CEO
    Wisp
  • Author:

    Mark Connell

    President
    SLBST Pharma

    Mark Connell

    President
    SLBST Pharma
  • Author:

    Asima Ahmad

    Co-Founder & Chief Medical Officer
    Carrot Fertility

    Asima Ahmad

    Co-Founder & Chief Medical Officer
    Carrot Fertility
  • Author:

    Andrea Olariu

    CEO
    Medicines360

    Andrea Olariu

    CEO
    Medicines360
  • Author:

    David Stern

    CEO
    Boston IVF

    David Stern has over 28 years of women’s health experience and has devoted the majority of his career to the fertility industry. He has held executive leadership positions and built successful teams while launching numerous products in pharmaceutical and biotech markets world-wide. Currently, David serves as the CEO of Boston IVF, one the largest IVF center networks in the United States with 11 full service IVF centers and over 30 satellite centers nationwide.

     

    David served as CEO of Symbiomix Therapeutics a venture backed biotech company. He led the transition of the company from development stage to commercial launch in the US, prior to its acquisition by Lupin Pharmaceuticals in 2017. He served on the board of California Cryobank and has held executive positions in startup companies in the women’s healthcare market, building commercial teams, developing strategy and expanding scientific partnerships for Celmatix, Ohana and OvaScience.

     

    David was the Senior Vice President and Head of the Global Business Franchise for Fertility at Merck Serono, responsible for the strategic development and growth of the portfolio world-wide. Prior to his global role, he was responsible for the US commercial operations in the Fertility, HIV and Growth Hormone markets. David started his career in women’s health with Organon Pharmaceutics. He has an MBA with a concentration in International Marketing and Management from the F.W. Olin School of Business at Babson College and holds a Bachelors’ degree in Biology from Brandeis University.

    David Stern

    CEO
    Boston IVF

    David Stern has over 28 years of women’s health experience and has devoted the majority of his career to the fertility industry. He has held executive leadership positions and built successful teams while launching numerous products in pharmaceutical and biotech markets world-wide. Currently, David serves as the CEO of Boston IVF, one the largest IVF center networks in the United States with 11 full service IVF centers and over 30 satellite centers nationwide.

     

    David served as CEO of Symbiomix Therapeutics a venture backed biotech company. He led the transition of the company from development stage to commercial launch in the US, prior to its acquisition by Lupin Pharmaceuticals in 2017. He served on the board of California Cryobank and has held executive positions in startup companies in the women’s healthcare market, building commercial teams, developing strategy and expanding scientific partnerships for Celmatix, Ohana and OvaScience.

     

    David was the Senior Vice President and Head of the Global Business Franchise for Fertility at Merck Serono, responsible for the strategic development and growth of the portfolio world-wide. Prior to his global role, he was responsible for the US commercial operations in the Fertility, HIV and Growth Hormone markets. David started his career in women’s health with Organon Pharmaceutics. He has an MBA with a concentration in International Marketing and Management from the F.W. Olin School of Business at Babson College and holds a Bachelors’ degree in Biology from Brandeis University.

  • Author:

    April Schweitzer

    Partner
    Nixon Peabody

    April Schweitzer is a partner in Nixon Peabody’s Healthcare practice group and is based of Chicago. She partners with provider clients to address corporate and regulatory issues affecting hospitals, health systems, and physician groups. She also provides counsel regarding value-based contracting, clinical integration networks, and accountable care organizations. Specifically, April works with clients on transactional matters including mergers, acquisitions, and joint ventures, as well as corporate governance, licensure, tax exemption, and formation issues. She also provides counsel to clients regarding EMTALA, the federal Anti-Kickback Statute, the federal Stark law, and state law equivalents, and Medicare and Medicaid regulatory compliance, including voluntary self-disclosures.

    April Schweitzer

    Partner
    Nixon Peabody

    April Schweitzer is a partner in Nixon Peabody’s Healthcare practice group and is based of Chicago. She partners with provider clients to address corporate and regulatory issues affecting hospitals, health systems, and physician groups. She also provides counsel regarding value-based contracting, clinical integration networks, and accountable care organizations. Specifically, April works with clients on transactional matters including mergers, acquisitions, and joint ventures, as well as corporate governance, licensure, tax exemption, and formation issues. She also provides counsel to clients regarding EMTALA, the federal Anti-Kickback Statute, the federal Stark law, and state law equivalents, and Medicare and Medicaid regulatory compliance, including voluntary self-disclosures.

  • Author:

    Juan Camilo Arjona Ferreira

    Head of Research & Development and Chief Medical Officer
    Organon

    Juan Camilo Arjona Ferreira

    Head of Research & Development and Chief Medical Officer
    Organon
  • Author:

    Alexandra Busto

    Partner
    Nixon Peabody LLP

    Alex Busto is a senior associate in Nixon Peabody’s Healthcare practice group and is based out of Los Angeles. She works with academic medical centers, hospitals, surgery centers, foundations and clinics, medical groups/IPAs, in-vitro fertilization and reproductive service providers, telehealth companies, MSOs, and other entities affiliated with the healthcare industry. Alex works closely with clients on transactional matters, and advises on multi-state expansion and growth, hospital/physician alignment, joint ventures, acquisitions, and other strategic transactions. In connection with these transactions, her practice also includes providing regulatory counsel with respect to federal and state compliance with physician self-referral, anti-kickback, licensing and certification, and other healthcare compliance matters.

    Alexandra Busto

    Partner
    Nixon Peabody LLP

    Alex Busto is a senior associate in Nixon Peabody’s Healthcare practice group and is based out of Los Angeles. She works with academic medical centers, hospitals, surgery centers, foundations and clinics, medical groups/IPAs, in-vitro fertilization and reproductive service providers, telehealth companies, MSOs, and other entities affiliated with the healthcare industry. Alex works closely with clients on transactional matters, and advises on multi-state expansion and growth, hospital/physician alignment, joint ventures, acquisitions, and other strategic transactions. In connection with these transactions, her practice also includes providing regulatory counsel with respect to federal and state compliance with physician self-referral, anti-kickback, licensing and certification, and other healthcare compliance matters.

  • Author:

    Charlotte Owens

    Head of Medical Affairs & Outcomes Research
    Organon

    Charlotte Owens

    Head of Medical Affairs & Outcomes Research
    Organon
  • Author:

    Dr Lyndsey Harper MD, FACOG IF

    Founder & CEO
    Rosy Wellness

    Dr Lyndsey Harper MD, FACOG IF

    Founder & CEO
    Rosy Wellness
  • Author:

    Maia Gokhale

    Vice President, Partner Success
    Mae

    Maia Gokhale

    Vice President, Partner Success
    Mae
  • Author:

    Thomas F. McElrath

    Associate Professor, Harvard Medical School
    Brigham and Women’s Hospital

    Thomas F. McElrath, MD, PhD:  Dr McElrath is a Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School and a Professor of Epidemiology at the Harvard TH Chan School of Public Health. For 25 years he has served as an attending physician in Maternal-Fetal Medicine at The Brigham and Women’s Hospital in Boston where he is the Director of the Preterm Birth Clinic and Principal Investigator of the LIFECODES birth cohort. He has a PhD in Mathematical Demography with ongoing research interests in two areas: the effects of environmental toxicant exposures in pregnancy and the utilization of biomarkers for the prediction of preterm birth and associated pregnancy complications.

    Thomas F. McElrath

    Associate Professor, Harvard Medical School
    Brigham and Women’s Hospital

    Thomas F. McElrath, MD, PhD:  Dr McElrath is a Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School and a Professor of Epidemiology at the Harvard TH Chan School of Public Health. For 25 years he has served as an attending physician in Maternal-Fetal Medicine at The Brigham and Women’s Hospital in Boston where he is the Director of the Preterm Birth Clinic and Principal Investigator of the LIFECODES birth cohort. He has a PhD in Mathematical Demography with ongoing research interests in two areas: the effects of environmental toxicant exposures in pregnancy and the utilization of biomarkers for the prediction of preterm birth and associated pregnancy complications.

  • Author:

    Dr. Sophia Yen

    Co-founder and Chief Medical Officer
    Pandia Health

    Dr. Sophia Yen

    Co-founder and Chief Medical Officer
    Pandia Health

Other events you might be interested in:

Women's Healthy Aging Innovation Summit

Women's Health Innovation Summit, Europe

Women's Health Innovation Summit 2024